Mayo Clinic

Mayo Clinic and nference form Qrativ, AI platform for developing rare disease therapies

Monday, July 24, 2017

The Mayo Clinic and nference, a healthcare data synthesis company powered by artificial intelligence (AI), recently announced they’re joining forces to form the startup company Qrativ. This startup will combine nference’s AI knowledge synthesis platform and the Mayo Clinic’s experience and expertise in medicine and healthcare to identify and develop new therapies for patients where an unmet need exists. Orphan diseases have been chosen as the prime focus of Qrativ’s efforts.

[Read More]

BioSig Technologies, Mayo Clinic partner

Friday, March 17, 2017

BioSig Technologies, a medical device company developing the PURE EP System, a proprietary platform designed to address an unmet technology need for the $4 billion electrophysiology (EP) marketplace, has signed a 10-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. This new, expanded collaboration with Mayo builds upon the work realized under the Advanced Clinical Research Program that was signed with Mayo Clinic in March 2016.

[Read More]

Curable initiates the International PSC Genome Project

Friday, November 18, 2016

Curable, a nonprofit research accelerator that applies engineering approaches to medicine to develop solutions for rare diseases, has announced the initiation of the International PSC Genome Project, which includes the Regeneron Genetics Center (RGC, a wholly-owned subsidiary of Regeneron Pharmaceuticals) and the Mayo Clinic with the goal of conducting the largest sequencing project for primary sclerosing cholangitis (PSC) to date.

[Read More]